好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Risk of readmission for injury in patients with epilepsy in the US
General Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-013

To determine 30-day injury readmissions risk amongst persons with epilepsy compared to individuals without epilepsy using a nationally representative US database.

Injury risk is higher in persons with epilepsy than in persons without epilepsy. To our knowledge, this is the first study to use the Nationwide Readmissions Database (NRD) to assess risk of injury readmissions after an epilepsy index hospitalization. 

Individuals of all ages with epilepsy as the primary diagnosis were identified using validated ICD-9-CM codes in the 2014 NRD. 1:4 matching on propensity scoring (by age, sex, Elixhauser comorbidity index) was performed to compare persons with epilepsy versus controls. Primary outcome was 30-day readmission for an injury defined by ICD-9-CM diagnosis codes following discharge from the index hospitalization. Logistic regression was conducted to examine factors associated with readmissions.

There were 66,339 unique persons with epilepsy (mean age 42.2 years, female 48.9%) and 331,695 without epilepsy (mean age 43.9 years, female 48.0%). 177 (0.25%) persons with epilepsy and 639 (0.23%) persons without epilepsy were readmitted for an injury. Statistically significant differences (p-value <0.05) in baseline demographics in persons with vs. without epilepsy included: Medicaid insurance (30.7 vs. 27.1%), discharge to a facility (16.4 vs. 12.4%), and hospital bed size (63.1% vs. 58.0%). In the multivariate analysis the following factors were associated with injury readmissions in persons with epilepsy: 1) Medicare (OR 2.8 95%CI 1.8-4.4) and Medicaid (OR 2.0 95%CI 1.2-3.6) vs. other insurance status; 2) discharge to a facility other than home (OR 1.5 95%CI 1.0-2.1).

Higher proportions of 30-day injury readmissions were observed in persons with epilepsy vs. without epilepsy. Our findings suggest that it may be important to further optimize discharge planning in persons with epilepsy on Medicare, Medicaid or being discharged to a facility, as their risk of injury appears to be greater. 

Authors/Disclosures
Yoni Goldstein
PRESENTER
No disclosure on file
Churl-Su Kwon, MBBS (Columbia University) Dr. Kwon has nothing to disclose.
Parul Agarwal Parul Agarwal has nothing to disclose.
Mandip S. Dhamoon, MD, MPH Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Faegre Baker Daniels LLP. Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wellstar Health System Inc. Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Fabiani Cohen & Hall, LLP. Dr. Dhamoon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Kramer, Dillof, Livingston & Moore. Dr. Dhamoon has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Robins Kaplan. Dr. Dhamoon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Parker Waichman LLP. Dr. Dhamoon has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Heidell, Pittoni, Murphy & Bach, LLP.
No disclosure on file
Nathalie Jette, MD, MSc, FRCPC, FAAN (University of Calgary) Dr. Jette has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE Epilepsia. The institution of Dr. Jette has received research support from NIH. The institution of Dr. Jette has received research support from AES.